Cyberonics — Merger or Acquisition (February 2015)
16 slides from Cyberonics's merger presentation, Feb 26, 2015
Slide 1: Creating a Premier Global Medical Technology Company
CREATING A PREMIER GLOBAL MEDICAL TECHNOLOGY COMPANY
Slide 2: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solic
Slide 3: Sorin Group and Cyberonics announce the creation of a leading global medical technology company
Diverse, market-leading product portfolio to drive shareholder value Technical and commercial scale across geographies to enhance revenue growth Focused innovation platform to exploit market opportunities and accelerate product development in Heart Failure, Sleep Apnea and Percutaneous Mitral Valve
Slide 4: Compelling strategic rationale
Compelling strategic rationale 4 Leadership in Large and Growing Markets Opportunities in Three Multi-Billion Dollar Specialty Markets Global Scale and Geographic Diversification Highly Complementary Technologies Strong Balance Sheet to Execute Plan
Slide 5: Cyberonics and Sorin at a glance
Revenue (2014)1 Cyberonics and Sorin at a glance 5 LTM figures as of January 23rd 2015 for Cyberonics. LTM figures as of December 31st 2014 for Sorin translated at an average exchange rate of $1.33/€1 Sutureless valve (PercevalTM) and Goal-Directed-Perfusion system CRT optimization system (SonRTM) N
Slide 6: Global scale and geographical diversification
Global scale and geographical diversification São Paulo, Brazil Cyberonics Manufacturing and offices Sorin Manufacturing and R&D Vancouver, BC Denver, CO Houston, TX Costa Rica Mirandola, Italy Meylan, France Saluggia, Italy Munich, Germany Clamart, France Louvain-la-Neuve, Belgium Dominican Republi
Slide 7: Highly complementary businesses
Highly complementary businesses LTM figures as of January 23rd 2015 for Cyberonics. LTM figures as of December 31st 2014 for Sorin translated at an average exchange rate of $1.33/€1 Geography Business Unit 7 Neuromodulation 100% International 20% US 80% International 77% US 23% Cardiac Surgery 67% C
Slide 8: Diversified product portfolio and broader geographical reach
$1.3bn ...leading to diversified product portfolio and broader geographical reach Pro forma 2014 revenues by geography1 Pro forma 2014 revenues by business1 8 LTM figures as of January 23rd 2015 for Cyberonics. 1) LTM figures as of December 31st 2014 for Sorin translated at an average exchange rate
Slide 9: Bringing together global leaders in Cardiac Surgery and Neuromodulation
Bringing together global leaders in Cardiac Surgery and Neuromodulation Leveraging an innovative Cardiac Rhythm Management platform Leadership in large and growing markets CARDIAC SURGERY NEUROMODULATION CRM Cardiopulmonary global leader #1 in Heart-lung machines #1 in Oxygenators Leading player in
Slide 10: Highly complementary technologies and selling capabilities
Highly complementary technologies and selling capabilities 10 Shared technologies Complementary commercialization capabilities Implantable electronics Neuromodulation Heart Failure Sleep Apnea CRM Wireless MRI-Compatibility Remote Monitoring ICD Leads VNS Science and Expertise Algorithms Closed-loop
Slide 11: Accelerated development and commercialization of new product categories
Accelerated development and commercialization of new product categories The combined opportunities leverage Cyberonics’ ability to develop markets and Sorin’s geographical reach Opportunities in billion dollar specialty markets 11 Heart Failure (HF) Sleep Apnea Percutaneous Mitral Potential market o
Slide 12: ~$80 million of annual pre-tax operating synergies by end of 2018
~$80 million of annual pre-tax operating synergies to be delivered by the end of 2018 Operating synergies driving significant incremental value Manufacturing Cyberonics’ leverage of Sorin’s commercialization network Neuromodulation revenue Capitalising on market relationships with wider product rang
Slide 13: Proven leadership team with strong track record
Proven leadership team with strong track record 13 André-Michel Ballester Chief Executive Officer CEO of Sorin Group since 2007 During tenure as CEO, he refocused the core business (divesting two non-core businesses), launched breakthrough products such as PercevalTM, InspireTM and SonRTM, restored
Slide 14: Transaction overview
Transaction overview 14 1) Based on the closing share price of Sorin Group and Cyberonics on 25 February 2015. Market capitalizations translated at €/$ exchange rate of 25 February 2015. 2) On a fully-diluted basis Transaction value Combined equity value of approximately $2.7 billion/€2.4 billion1 N
Slide 15: Driving significant shareholder returns
Driving significant shareholder returns Revenue growth acceleration Stronger and more diversified platform for growth Significant revenue potential from highly complementary Heart Failure programs Leverage Sorin’s commercialization network for Neuromodulation Synergies Approximately $80 million annu
Slide 16: Contacts
Contacts 16 FOR CYBERONICS, INC.: Investors: Greg Browne CFO Cyberonics, Inc. Tel: +1 281 228 7262 e-mail: ir@cyberonics.com Media: Sard Verbinnen & Co New York: Andrew Cole / Chris Kittredge Tel: +1 212 687 8080 London: Conrad Harrington +44 020 3178 8914 FOR SORIN GROUP: Investors: Demetrio Mauro